USX:STTK - Shattuck Labs, Inc Shattuck Labs, Inc
Sector: Health Care, Industry: Biotechnology
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 30.3    +0.960 (+3.27%)
Show Technical Chart | 1M    3M    6M    1Y    3Y    5Y         

21 Jun 2021


Loading...
Loading...
Loading...

General

CEO: Mr. Josiah C. Hornblower

IPO: 2020-10-09

Headquarters: US

Employees: 59

Homepage

Description

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.